Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | OSU-T315 |
Trade Name | |
Synonyms | OSUT315|OSU T315 |
Drug Descriptions |
OSU-T315 is an ILK inhibitor potentially inhibiting Akt signaling and inducing tumor cell cytotoxicity (PMID: 32439931, PMID: 25293770). |
DrugClasses | |
CAS Registry Number | 2070015-22-2 |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ARQ 751 + OSU-T315 | ARQ 751 OSU-T315 | 1 | 0 |
GSK690693 + OSU-T315 | GSK690693 OSU-T315 | 1 | 0 |
Ipatasertib + OSU-T315 | Ipatasertib OSU-T315 | 2 | 0 |
Miransertib + OSU-T315 | Miransertib OSU-T315 | 2 | 0 |
MK2206 + OSU-T315 | MK2206 OSU-T315 | 1 | 0 |
OSU-T315 | OSU-T315 | 0 | 0 |